Krasen I.
- Country
- Bulgaria
- Department
- NA
Research Overview
- Pharmacokinetic Evaluation of AMX0035 in Subjects with Hepatic Impairment and Healthy Controls
- Evaluation of Camizestrant Pharmacokinetics, Safety, and Tolerability in Post-Menopausal Females with Moderate or Severe Hepatic Impairment
- Evaluation of Safety, Tolerability, and Pharmacokinetics of Tideglusib in Patients with Hepatic Impairment Compared to Healthy Controls
Data & Insights
Has run more than one trial at 2 of 4 partner sites.
Specializations
Dermatology and Inflammatory Skin Disease
Krasen Ivanov is involved in clinical research focused on moderate to severe plaque psoriasis, with attention to long-term treatment outcomes, safety, tolerability, and sustained disease control.
- Plaque psoriasis
- Inflammatory skin disease
- Long-term safety
- Treatment tolerability
This area reflects a therapeutic interest in chronic immune-mediated skin disorders and their ongoing clinical management.
Hepatic Impairment and Pharmacokinetics
His research includes studies in participants with hepatic impairment, covering both moderate to severe hepatic dysfunction and the evaluation of how liver impairment affects drug exposure, safety, and tolerability.
- Hepatic function
- Drug disposition
- Safety in liver impairment
- Post-menopausal female subjects
This field connects liver-related clinical assessment with therapeutic use in populations requiring careful pharmacological characterization.
Renal Impairment and Clinical Pharmacology
Krasen Ivanov is also involved in research among participants with renal impairment, with emphasis on understanding how reduced kidney function influences pharmacokinetics, tolerability, and overall treatment suitability.
- Renal function
- Clinical pharmacology
- Impaired renal function
- Healthy participants
These studies support therapeutic evaluation in populations where renal status is central to medication use and monitoring.
Healthy Volunteers and Reference Populations
His trial portfolio includes healthy volunteers as a comparator population, contributing to research that establishes baseline pharmacokinetic and safety profiles across different physiological states.
- Healthy participants
- Reference populations
- Comparative pharmacology
- Tolerability assessment
This area supports the clinical interpretation of therapeutic performance across both impaired and non-impaired study groups.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.